Page last updated: 2024-08-24

fenofibric acid and Non-alcoholic Fatty Liver Disease

fenofibric acid has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y1
Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K1
Chew, GT; Sahebkar, A; Watts, GF1

Reviews

2 review(s) available for fenofibric acid and Non-alcoholic Fatty Liver Disease

ArticleYear
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10

    Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary

2020
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4

    Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides

2014

Other Studies

1 other study(ies) available for fenofibric acid and Non-alcoholic Fatty Liver Disease

ArticleYear
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    International journal of molecular sciences, 2022, Apr-25, Volume: 23, Issue:9

    Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma

2022